Literature DB >> 2983788

ACTH, cortisol, and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery.

F Holsboer, A Gerken, G K Stalla, O A Müller.   

Abstract

Synthetic ovine corticotropin releasing factor (o-CRF) was administered as an intravenous bolus (100 micrograms) to eight patients suffering from a major depressive disorder, endogenous subtype. All patients showed inadequately suppressed cortisol levels after 1 mg dexamethasone. After clinical remission and normalized dexamethasone responses, these patients were reinvestigated with o-CRF stimulation. The mean adrenocorticotropic hormone (ACTH) release from the pituitary corticotroph cells was indiscriminate at both test sessions. Cortisol and corticosterone output after o-CRF tended to be higher during depression than after recovery. The o-CRF-induced increments observed with corticosterone were more marked in comparison with cortisol. Within the limitations of the current protocol, our preliminary data lend support to the view that an increased pituitary ACTH reserve or adrenocortical steroid reserve is not likely to be responsible for the defective pituitary-adrenal regulation in some dexamethasone-resistant depressives.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983788     DOI: 10.1016/0006-3223(85)90057-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Fawn-hooded rats show enhanced active behaviour in the forced swimming test, with no evidence for pituitary-adrenal axis hyperactivity.

Authors:  A Lahmame; F Gomez; A Armario
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 2.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

Review 3.  A narrative review on the difficulties associated with fibromyalgia diagnosis.

Authors:  Dinesh Kumbhare; Sara Ahmed; Scott Watter
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-12-07       Impact factor: 5.346

Review 4.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Neuroimmunological function in parents of children suffering from cancer.

Authors:  Noa Benaroya-Milshtein; Alan Apter; Isaac Yaniv; Oded Yuval; Boaz Stern; Yael Bengal; Yona Kodman; Eliya Shemer; Chaim Gideon Pick; Ilana Buchval; Avi Valevski
Journal:  J Neural Transm (Vienna)       Date:  2013-10-23       Impact factor: 3.575

6.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.

Authors:  Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 8.  Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.

Authors:  Nicholas Barden
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

9.  Fetal hormonal programming of sex differences in depression: linking women's mental health with sex differences in the brain across the lifespan.

Authors:  Jill M Goldstein; Laura Holsen; Robert Handa; Stuart Tobet
Journal:  Front Neurosci       Date:  2014-09-08       Impact factor: 4.677

10.  The Research of the Effect of the Olive Juice on Anxiety and Depression Behavior.

Authors:  Jiguo Zhang
Journal:  Open Biomed Eng J       Date:  2015-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.